The National Amyotrophic Lateral Sclerosis Registry
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.
| Condition |
|---|
|
Amyotrophic Lateral Sclerosis |
| Study Type: | Observational [Patient Registry] |
| Target Follow-Up Duration: | 5 Years |
| Official Title: | The National Amyotrophic Lateral Sclerosis Registry |
- The National Amyotrophic Lateral Sclerosis (ALS) Registry [ Time Frame: 1 year ] [ Designated as safety issue: No ]To determine the incidence and prevalence of Amyotrophic Lateral Sclerosis in the US.
- Risk factors of ALS [ Time Frame: 1 year ] [ Designated as safety issue: No ]To learn more about the potential risk factors for ALS
| Estimated Enrollment: | 5000 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
ALS cases in the United States
Inclusion Criteria:
- U.S. citizens 18 years of age or older
Exclusion Criteria:
-
Contacts and Locations| Contact: Oleg Muravov, MD, PhD | omuravov@cdc.gov |
| United States, Georgia | |
| Centers for Disease Control and Prevention | Recruiting |
| Atlanta, Georgia, United States, 30333 | |
| Contact: Oleg Muravov, MD, PhD 770-488-3817 omuravov@cdc.gov | |
| Principal Investigator: Oleg Muravov, MD, PhD | |
| Principal Investigator: | Oleg Muravov, MD, PhD | Centers for Disease Control and Prevention |
More Information
Additional Information:
No publications provided
| Responsible Party: | Centers for Disease Control and Prevention |
| ClinicalTrials.gov Identifier: | NCT01772602 History of Changes |
| Other Study ID Numbers: | CDC-NCEH/ATSDR-5768 |
| Study First Received: | January 17, 2013 |
| Last Updated: | January 22, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Centers for Disease Control and Prevention:
|
Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Motor Neuron Disease |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Sclerosis Motor Neuron Disease Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases |
Neurodegenerative Diseases TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on May 16, 2013